ARAY (Accuray) Common Stock : $0.1 Mil (As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Accuray Common Stock?

Accuray's quarterly common stock stayed the same from Jun. 2024 ($0.1 Mil) to Sep. 2024 ($0.1 Mil) but then increased from Sep. 2024 ($0.1 Mil) to Dec. 2024 ($0.1 Mil).

Accuray's annual common stock increased from Jun. 2022 ($0.1 Mil) to Jun. 2023 ($0.1 Mil) and increased from Jun. 2023 ($0.1 Mil) to Jun. 2024 ($0.1 Mil).

Accuray Common Stock Historical Data

The historical data trend for Accuray's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accuray Common Stock Chart

Accuray Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Common Stock

Get a 7-Day Free Trial

0.09

0.10

Accuray Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															0.10	0.10	0.10	0.10	0.10

Accuray Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Accuray Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accuray Inc (NAS:ARAY) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

0H8I:UK XEJ:Germany

Address

1240 Deming Way, Madison, WI, USA, 53717

Website

https://www.accuray.com

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Executives

Ali Pervaiz	officer: SVP Chief Financial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Joseph E Whitters	director
Michael Hoge	officer: Senior VP Global Operations	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Gina Corradetti	officer: VP, Corporate Controller	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Jesse Chew	officer: SVP and General Counsel	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Sandeep Chalke	officer: SVP, Chief Commercial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Suzanne C Winter	officer: SVP & Chief Commercial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Patrick Spine	officer: SVP, Chief Admin Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Kill	director	VIRTUAL RADIOLOGIC CORPORATION, 5995 OPUS PARKWAY, SUITE 200, MINNETONKA MN 55343
Brandon W Green	officer: Chief Financial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Franco N Palomba	officer: VP, Chief Accounting Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Byron C Scott	director	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Joshua Levine	officer: President & CEO	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Mika Nishimura	director	471 EL CAMINO REAL, SANTA CLARA CA 95050
Shigeyuki Hamamatsu	officer: VP, Finance and CAO	1875 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043